These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34620004)

  • 1. Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With
    Fusco MJ; Piña Y; Macaulay RJ; Sahebjam S; Forsyth PA; Peguero E; Walko CM
    Cancer Control; 2021; 28():10732748211040013. PubMed ID: 34620004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained Tumor Control With MAPK Inhibition in
    Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
    Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy in Advanced Melanoma With Rare
    Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
    J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent BRAF/MEK Inhibitors in
    Schreck KC; Guajardo A; Lin DDM; Eberhart CG; Grossman SA
    J Natl Compr Canc Netw; 2018 Apr; 16(4):343-347. PubMed ID: 29632053
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
    Piña Y; Fusco MJ; Macaulay RJ; Walko CM; Peguero E; Evernden BR; Smalley KS; Forsyth P
    J Neurol; 2020 Mar; 267(3):783-790. PubMed ID: 31748891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of targeting
    Smith-Cohn M; Davidson C; Colman H; Cohen AL
    CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
    [No Abstract]   [Full Text] [Related]  

  • 9. Dabrafenib and trametinib in BRAFV600E mutated glioma.
    Brown NF; Carter T; Kitchen N; Mulholland P
    CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma proteome alterations by MAPK inhibitors in BRAF
    Babačić H; Eriksson H; Pernemalm M
    Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
    Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
    Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
    Santiago-Walker A; Gagnon R; Mazumdar J; Casey M; Long GV; Schadendorf D; Flaherty K; Kefford R; Hauschild A; Hwu P; Haney P; O'Hagan A; Carver J; Goodman V; Legos J; Martin AM
    Clin Cancer Res; 2016 Feb; 22(3):567-74. PubMed ID: 26446943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
    Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors.
    Preusser M; Bienkowski M; Birner P
    Expert Opin Investig Drugs; 2016; 25(1):7-14. PubMed ID: 26536389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Dabrafenib in Pediatric Patients with
    Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
    Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
    N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
    BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.